08:30 | Conference Registration, Materials Pick-Up, Morning Tea, Coffee and Networking |
| Exosomes in Biology and Disease |
| Session Chair: Murray Mitchell, Professor, University of Queensland Centre for Clinical Research, Australia |
| |
09:30 | | Keynote Presentation The Role of Extracellular Vesicles in Neurodegenerative Diseases Andrew Hill, Professor, La Trobe University; ISEV President, Australia
Neurodegenerative disorders such as Alzheimer’s (AD), Parkinson’s (PD) and prion diseases are associated with proteins that misfold and deposit in the brain. Many cell types, including neurons, release extracellular vesicles (EVs) which include microvesicles and exosomes. EVs have been shown to be involved in processing of proteins such as APP, a-synuclein, and PrP which are those involved in AD, PD and prion diseases respectively. Roles for these vesicles include cell-cell signalling, removal of unwanted proteins, and transfer of pathogens (including prion-like misfolded proteins) between cells. In addition to their protein content these vesicles have recently been shown to contain genetic material in the form of protein coding (mRNA) and noncoding RNA species. We have analysed the protein and genetic cargo of EVs from a number of cell types and using deep sequencing, characterised the RNA cargo of these vesicles. Here, the role of extracellular vesicles in the pathogenesis and potential diagnosis of neurodegenerative diseases will be discussed. |
|
10:15 | The Characterisation and Function of Exosomes Derived from Human T Regulatory Cells Lesley Smyth, Senior Lecturer in Immunology, University of East London, United Kingdom
Regulatory T-cells (Tregs) maintain immune tolerance to self-antigens and prevent excessive pro-inflammatory actions of T-effectors (Teffs) and antigen presenting cells responses. In a murine setting, these cells inhibit the aforementioned cells in a variety of ways including the release of extracellular vesicles (EVs). Release of these vesicles plays a key role in the suppressive capability of murine Tregs through the expression of the ectoenzyme CD73 and specific miRNA species. We have now extended this observation to human CD4+CD25+127lo T-cells isolated from blood, and cultured in the presence of anti-CD3/CD28-coated beads, rapamyacin and IL-2. These cells were suppressive and display key molecules associated with regulation. Activated human Tregs released 50-100nm-sized EVs expressing CD63 and CD81 as well as CD25 and CD39. Excitingly, Treg Evs were capable of suppressing Teffs responses resulting in less activation and the production of an anti-inflammatory cytokine profile. Their suppressive capabilities were also evident in vivo. Adoptive transfer of Treg EVs prevented T cell infiltration and skin damage in a humanised model of transplantation. Our data highlights that human Tregs produce EVs following activation and that this is a novel mechanism by which human Tregs modify immune Teff responses in vivo. |
10:45 | Procoagulant Extracellular Vesicles in Hemostasis and Thrombosis Nigel Mackman, Distinguished Professor of Medicine, University of North Carolina at Chapel Hill, United States of America
The coagulation cascade consists of a series of cofactor/protease complexes (tissue factor (TF)/FVIIa; FVIIIa/FIXa; FVa/FXa) that assemble on membrane surfaces and result in the formation of fibrin. TF is a transmembrane receptor for FVII/FVIIa and the TF/FVIIa complex is the major initiator of the clotting cascade. The clotting cascade plays an essential role in hemostasis but also contributes to pathologic thrombosis. Several coagulation proteases (FIX, FX, FVII and prothrombin) contain a Gla domain that is positively-charged. Normal cells have an asymmetric membrane with negatively-charged phospholipids, such as phosphatidylserine (PS), located on the inner leaflet of the membrane. However, after cell damage PS flips to the outer leaflet of the membrane where it facilitates the binding and assembly of Gla-containing coagulation proteases and activation of coagulation at sites of injury. Extracellular vesicles (EVs) are small vesicles derived from activated or apoptotic cells. There are several types of EVs that can enhance coagulation depending on the presence of exposed PS and TF. For instance, PS-,TF- EVs have the lowest procoagulant activity (PCA) whereas PS+,TF+ EVs have the highest PCA. The majority of EVs in blood are derived from platelets and were originally described as platelet dust. These PS+ and PS-EVs can enhance ongoing coagulation but cannot trigger coagulation. In contrast, EVs derived from activated monocytes and many types of tumors express PS and TF and can activate coagulation. PS+,TF+ EVs have been detected in the blood of patients with experimental endotoxemia, liver injury, cirrhosis, sickle cell disease, influenza A infection and cancer. These EVs likely contribute to thrombosis in these patients. Several prospective studies found that increased levels of TF+ EV precede venous thrombosis in pancreatic cancer patients. These studies suggest that TF+EVs could be used as a biomarker to identify patients at increased risk for venous thrombosis. |
11:15 | Coffee and Tea Break and Networking in the Exhibit Hall |
11:45 | Cellular Stress Sensor mTORC1 Switches Exosome Biogenesis and Secretion Pathways to Influence the Tumour Microenvironment Deborah Goberdhan, Associate Professor of Cell Signalling, University of Oxford, United Kingdom
I will discuss our data describing a new mechanism of exosome biogenesis, conserved between humans and flies. We show that reduced signalling from the cellular mTORC1 micro-environmental sensor, in glutamine-depleted conditions, causes changes in membrane trafficking and an upregulation of this alternate mechanism of exosome production. This leads to the secretion of stress-induced exosomes, which induce adaptive responses in recipient cancer cells. |
12:15 | Role of Exosomes in the Transport of Amyloid Precursor Protein Fragments Between Neurons Rémy Sadoul, Professor, Université Grenoble Alpes, France
Amyloid beta peptide (A?), the main component of senile plaques of Alzheimer’s disease brains, is produced by cleavage of the C-terminal transmembrane fragments (CTFs) of Amyloid Precursor Protein (APP). An unanswered question is how pathological amyoidogenic peptides spread throughout the brain during the course of the disease. We have shown that cortical neurons secrete exosomes which specifically bind to, and are endocytosed by other neurons. Cortical exosomes, carry endogenous APP and are strikingly enriched in CTFs. Using N2a cells expressing human APP and the tetraspanin CD63, we also found that the two proteins are sorted to different subsets of exosomes. We also found that APP carrying exosomes specifically bind to neurons in contrast to CD63-carrying exosomes, which bind to both neurons and glial cells. Thus, neuroblastoma cells secrete distinct populations of exosomes carrying different cargoes and targeting specific cell types. APP-carrying exosomes can be endocytosed by receiving cells allowing the processing of APP acquired by exosomes to give rise to the APP intracellular domain (AICD). Thus, our results show for the first time that neuronal exosomes may indeed act as vehicles for the intercellular transport of APP and its catabolites. |
12:45 | Networking Lunch in the Exhibit Hall -- Meet the Exhibitors and View Posters |
| Session Title: Extracellular Vesicles -- Technologies, Approaches and Engineering |
| |
14:00 | Technology Spotlight: High-Throughout Characterization of Single Exosomes and Extracellular Vesicles George Daaboul, Chief Scientific Officer, nanoView Biosciences, Inc.
To accurately characterize exosomes it is necessary to validate prepared samples, which is most commonly performed using nanoparticle tracking analysis (NTA) combined with proteomic analysis for exosomal proteins. As an alternative to this, Flow Cytometry (FC) has recently been used to combine the sizing and proteomic information into a single measurement. While FC is a mature tool for large cellular-sized analyses, there are a number of limitations that stem from the small-size of exosomes, specifically in terms of the number of available surface epitopes and low-signal relative to background levels, especially in complex samples. To improve the characterization of exosomes, nanoView Diagnostics has developed a label-free visible-light microarray imaging technique that allows multiplexed enumeration and sizing of individual nanovesicles captured on the sensor in a one-step assay direct-from-sample and can work with samples volumes as small as 5 µl. The exosome characterization technology collapses a number of steps into a 1-step high-throughput technique that can improve standardization of exosome preparations and facilitate translation of exosome based liquid biopsies and therapeutic developments. |
14:30 | Technology Spotlight: Development of a Sensitive and Robust NGS Protocol for microRNA Sequencing in Exosome and Extracellular Vesicle Samples Laura Klitten, Global Product Manager, Exiqon – a QIAGEN company
The contents of exosomes are subject of investigative efforts worldwide, from basic research to biomarker discovery, with the goal of using insights for diagnostic and therapeutic purposes. The profile of microRNAs contained in exosomes can elucidate cellular functions and responses in diseased and healthy states. Plasma-derived exosomes are commonly isolated by differential centrifugation, which has proven to be difficult and is susceptible to variability in experience and skill of the person performing the isolation. To assess and optimize methodologies for the isolation and characterization of microRNAs in liquid biopsies, plasma samples from three immunized animals were prepared for next generation sequencing using three different methods: Exosome preparation by differential centrifugation, exosome preparation with the miRCURY™ isolation technology, and no exosome prep -RNA was isolated directly from the plasma sample. Library preparation and subsequent sequencing was successful for all preparation methods, with mapping percentages above 75% for all samples. Overall, provided that protocols optimized for liquid biopsies are used, there is good agreement between the microRNA expression patterns detected from whole plasma and isolated exosomes. This consistency across preparation methods attests to the high-quality and robust results that Exiqon Services achieves through experience and implementation of carefully designed and standardized protocols. |
15:00 | Composition and Regulatory Activities of Extracellular Vesicles Released by Osteoclasts Shannon Holliday, Associate Professor of Orthodontics and Anatomy & Cell Biology, University of Florida, United States of America
Communication between osteoclasts and osteoblasts is vital to maintain healthy bone. We have found osteoclasts release EVs that regulate osteoblasts. We have performed comprehensive proteomic profiling of these EVs, and are exploring their use in bone regeneration. |
15:30 | Afternoon Coffee and Tea Break and Networking in the Exhibit Hall |
16:00 | Live Tracking of Endogenous Exosomes in vivo Guillaume Van Niel, Team leader Endosomal Dynamic in Neuropathies, Institute Curie, France
Despite of their promising use as biomarkers and drug vehicles, very little is known about the dynamic of extracellular vesicles (EVs) secretion and their physiology in vivo. Here we proposed to fill this gap by developing a hCD63-based fluorescent reporter that allowed us to analyze their secretion in live cells and to track them from their site of production to their final destination in in vivo models. The use of this construct in cell lines revealed specific features and new stimulatory pathway of exosome secretion. The use of this construct in zebrafish embryos allowed us to observe exosome release in vivo and track a massive pool of endogenous exosomes in the blood flow by combining light- and electron microscopy techniques. After cell specific expression of the construct in vivo, we tracked endogenous exosomes by live imaging in the blood flow to identify their main targets. The mapping of the transit routes and final destination of EVs in zebrafish embryos support their role in nutrient delivery during development. Altogether, our work highlights the use of fluorescent reporter to study the regulation of exosome secretion and the use of the zebrafish embryo as a relevant vertebrate model to track endogenous EVs in vivo. |
16:30 | Mechanisms for the Selective Incorporation of Tissue Factor into Extracellular Vesicles Camille Ettelaie, Lecturer in Biomedical Science, University of Hull , United Kingdom
Incorporation of tissue factor into cell-derived microvesicles results in the release of procoagulant microvesicles. The incorporation of tissue factor into the microvesicles is regulated through mechanisms that include various elements within the cytoplasmic and transmembrane domain of this protein. The presentation will examine some of these known regulatory elements. |
17:00 | EVs as Modulators of Cellular Response During Chemotherapy David Carter, Reader in Biomedical Science, Oxford Brookes University, United Kingdom
We have previously shown that stress induces a bystander effect that is mediated by extracellular vesicles (EVs). These EVs can be taken up by bystander cells and induce a stress response that can last several generations. Here we show that bystander cells are more resistant to future stress, and that blocking EV-mediated communication during chemotherapy can sensitise cells to the effects of such drugs. |
17:30 | Profiling EV Subsets and Cargo to Enable Adaptive Tumor- and Immuno-therapies Jennifer Jones, NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, United States of America Joshua Welsh, Research Fellow, National Cancer Institute (NCI), NCI, United States of America
Exosomes and small viruses fall below the detection limits of conventional flow cytometers, which has limited ways to identify, sort, and study, distinct subsets of EVs and other nanoparticles as single particles. In order to maximize information and material that can be obtained with high speed, high resolution flow cytometers we have developed nanoscale Fluorescence Associated Cytometric Sorting (nanoFACS). We have demonstrated nanoFACS to be capable of detecting tumor-cell derived EVs with specific tumor antigens, such as Prostate Specific Membrane Antigen (PSMA), with fluorescence and scattered light parameters, as well as being capable of sorting two distinct HIV strains (85-125 nm) to >95% purity. The development of our nanoFACS method provides a unique way to analyze and sort functional EV- and viral-subsets, while preserving vesicular structure, surface protein specificity, and RNA cargo activity. |
18:00 | Close of Day 1 of the Conference |